Mobile

A randomised, double blind, placebo controlled, parallel study to assess the benefits of aclidinium bromide in the relief of COPD (Chronic obstructive pulmonary disease) symptoms including cough when...

Mise à jour : Il y a 4 ans
Référence : EUCTR2014-004715-37

A randomised, double blind, placebo controlled, parallel study to assess the benefits of aclidinium bromide in the relief of COPD (Chronic obstructive pulmonary disease) symptoms including cough when administered to patients with COPD

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

1. To assess the effect of aclidinium bromide 400 µg administered twice a day on COPD symptoms including cough in patients with moderate COPD compared to placebo. 2. To assess the effects of aclidinium bromide 400 µg administered twice a day in cough related quality of life measures when administered to the same target population.

Critère d'inclusion

  • Chronic Obstructive Pulmonary Disease (COPD)

Liens